Cardinal Health, Inc.

NYSE:CAH

Medical - Distribution

Healthcare
$278.32 -1.66%

-$3.77 today

Market cap
$64.33B
Beta
0.53
P/E (TTM)
33.5
EPS (TTM)
$6.63
Dividend yield
0.92%
52W Low $137.75High $233.60

Volume 1.35M

Average 2.11M

CAH Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Cardinal Health, Inc.NYSE: CAH

Research & Development · Q1 FY2027 · quarter ended Sep 2026

Research & development remains negative

Q1 FY2027 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2026, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearJun 2026
$0— YoY
LTMSep 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2026
0 USD
Year-over-year change
—

Research & Development vs competitors

How CAH compares with its peers on the latest reported figures

  • CAH's LTM Sep 2026 research & development of $0 is the highest of the 4 companies compared; the peer median is $0.
  • Research & development amounts to 0.0% of revenue for CAH, versus a peer median of 0.0%.
CAH Competitors Peer median
Research & Development for CAH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAHCardinal Health, Inc.LTM Sep 2026$0 ——0.0%
MCKMcKesson CorporationLTM Jun 2026$0 —+5.0%0.0%
CORCencora, Inc.LTM Jun 2026$0 ——0.0%
HSICHenry Schein, Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding CAH) $0—+5.0%0.0%

Competitors are the stored peer set for CAH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue181.33B204.98B226.83B222.58B254.25B
Cost of Revenue174.84B198.11B219.41B214.41B244.47B
Gross Profit6.48B6.89B7.41B8.17B9.77B
Gross Margin3.6%3.4%3.3%3.7%3.8%
Research & Development00000
Selling, General & Admin4.51B4.8B5B5.38B6.13B
Operating Expenses7.09B6.12B6.17B5.89B7.16B
Depreciation & Amortization692M692M710M790M956M
EBITDA55M1.44B1.96B3.11B3.48B
EBITDA Margin0.0%0.7%0.9%1.4%1.4%
Operating Income(607M)752M1.24B2.28B2.61B
Operating Margin-0.3%0.4%0.5%1.0%1.0%
Interest Income00000
Interest Expense147M84M51M215M348M
Other Income / Expenses(177M)(89M)(42M)(174M)(439M)
Income Before Tax(784M)663M1.2B2.1B2.17B
Pre-Tax Margin-0.4%0.3%0.5%0.9%0.9%
Income Tax Expense153M332M348M532M469M
Net Income(938M)330M852M1.56B1.71B
Net Margin-0.5%0.2%0.4%0.7%0.7%
EPS (Basic)(3.34)1.263.486.487.27
EPS (Diluted)(3.34)1.263.456.457.23
Weighted Avg Shares279M261M245M241M236M
Weighted Avg Shares (Diluted)279M262M247M242M237M

Cardinal Health, Inc.

NYSE:CAH

Intrinsic Alpha fair value

Locked

Current Price

$278.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.